However, if overexpression of PGK1 was supplemented with HSP90 ATPase inhibitor 17-AAG (Fig. 6a-b) or ERK pathway inhibitor PD98059 (Fig. 6c-d) (Alessi et al., 1995), the sensitivity of the endometrial cancer cell lines to cisplatin was restored. The gene discussed is PGK1; the disease is endometrial cancer.